Means and Methods for Diagnosing Heart Failure in a Subject

A method for diagnosing heart failure comprising the steps of:

• a. determining in a sample of a subject the amounts of at least three biomarkers, wherein said at least three biomarkers are:
• i. at least one triacylglyceride, at least one cholesterylester, and at least one phosphatidylcholine;
• ii. at least one triacylglyceride, at least one phosphatidylcholine, and at least one sphingomyelin;
• iii. at least one triacylglyceride, at least one cholesterylester, and at least one sphingomyelin;
• iv. at least one phosphatidylcholine, at least one cholesterylester, and at least one sphingomyelin;
• v. Cholesterylester C18:2, SSS and Cer(d17:1/24:0);
• vi. at least two sphingomyelins selected from the group consisting of SM2, SM3, SM5, SM18, SM23, SM24, and SM28, and at least one triacylglyceride selected from the group consisting of SOP2, SPP1 or PPO1;
• vii. at least two triacylglycerides selected from the group consisting of OSS2, SOP2, SPP1 and SSP2, and at least one sphingomyelin selected from the group consisting of SM23 and SM24;
• viii. SM18, SM24 and SM28;
• ix. the biomarkers of panel 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, or 199 of Table 2, or
• x. the biomarkers of panel 200, 201, 202, 203, 204, 205, or 206 of Table 2a, and
• b. comparing the amounts as determined in step a. to a reference, whereby heart failure is to be diagnosed,
• wherein the at least one triacylglyceride biomarker in i., ii., and iii. is selected from the group consisting of SOP2, OSS2, SPP1, SSP2, PPO1 and PPP, the at least one cholesterylester biomarker in i., iii., and iv. is selected from the group consisting of cholesterylester C18:2 and cholesterylester C18:0, the at least one phosphatidylcholine biomarker in i., ii. and iv. is selected from the group consisting of PC4 and PC8, and the at least one sphingomyelin biomarker in ii., iii., and iv. is selected from the group consisting of SM18, SM24, SM23, SM21, SM28, SM5, SM3, SM29 and SM8.